methylene blue fails

Tau Drug Flops in Study

A derivative of methylene blue fails in phase III trial

• SAVESAVED

• Activate MedPage Today's CME feature and receive free CME credit on Medical stories like this one.
  ACTIVATE CME

• 
 

• by Kristina Fiore 
  Associate Editor, MedPage Today

Action Points

TORONTO -- A derivative of methylene blue that's supposed to block tau aggregation in mild-to-moderate Alzheimer's disease failed in a phase III study, researchers reported here.